So-Rosillo Rosendo, Small Eric J
Hematology/Oncology, University of California, 505 Parnassus Avenue, M1286 San Francisco, CA 94143-1270, USA.
Expert Rev Anticancer Ther. 2006 Sep;6(9):1163-7. doi: 10.1586/14737140.6.9.1163.
Sipuleucel-T (Provenge; APC8015; Dendreon Corp, WA, USA) is a novel immunotherapeutic cellular product, which includes autologous dendritic cells pulsed ex vivo with a recombinant fusion protein (PA2024) consisting of granulocyte macrophage colony-stimulating factor and prostatic acid phosphatase. Two Phase II trials in men with androgen-dependent biochemically relapsed prostate cancer have demonstrated a decrease in prostate-specific antigen and prolongation in prostate-specific antigen doubling time. In men with hormone-refractory prostate cancer, clinical trials have demonstrated both biological activity and clinical response to sipuleucel-T. Data from two Phase III trials in men with asymptomatic, metastatic hormone-refractory prostate cancer demonstrated an improved median overall survival in men who received sipuleucel-T compared with placebo. Clinical trials are ongoing or are being developed to evaluate sipuleucel-T in various prostate cancer disease states and in combination with other treatment modalities.
西普乐昔-T（普罗文奇；APC8015；美国华盛顿州丹德昂公司）是一种新型免疫治疗细胞产品，它包括经体外与由粒细胞巨噬细胞集落刺激因子和前列腺酸性磷酸酶组成的重组融合蛋白（PA2024）脉冲处理的自体树突状细胞。两项针对雄激素依赖性生化复发前列腺癌男性患者的II期试验已证明前列腺特异性抗原降低，且前列腺特异性抗原倍增时间延长。在激素难治性前列腺癌男性患者中，临床试验已证明西普乐昔-T具有生物活性和临床反应。两项针对无症状转移性激素难治性前列腺癌男性患者的III期试验数据表明，与安慰剂相比，接受西普乐昔-T治疗的男性患者中位总生存期有所改善。目前正在进行或正在开展临床试验，以评估西普乐昔-T在各种前列腺癌疾病状态下以及与其他治疗方式联合使用的效果。
